According to an expert, the corona vaccine from Novavax, which has been newly approved in the EU, is much better suited for boosting than vector vaccines.
The corona vaccine from the US manufacturer Novavax is officially allowed in the EU *. Novavax is the fifth corona vaccine approved in the EU, but the first of its kind. Because “Nuvaxovid” is not an mRNA or vector-based vaccine, but a protein-based vaccine. echo24.de * already explained how the protein-based corona vaccine from Novavax works *. According to an expert, Novavax is “significantly better” than the vector vaccines AstraZeneca and Johnson & Johnson, especially with regard to booster vaccinations.
“Everything that is known so far indicates that Novavax is probably a very good vaccine,” said the Secretary General of the German Society for Immunology, Carsten Watzl, to the Augsburger Allgemeine . The effectiveness of Novavax * in the registration study with regard to diseases was 90 percent. This means that 90 percent fewer diseases occurred among the subjects in the vaccinated group than among the subjects in a control group.
A lot is already known about the possible side effects of Novavax *. In the pivotal study, two doses were given three weeks apart. First results indicate that the vaccination protection of Novavax wears off over time * – as with the other corona vaccines. But is “Nuvaxovid” also suitable as a booster vaccine?
Novavax vaccine is suitable as a booster “better than vector vaccines”
According to experts, vaccine from the US manufacturer Novavax is generally also suitable for booster vaccinations. “According to a British study, Novavax is not quite as effective as the mRNA vaccines for booster vaccinations, but it is significantly better than vector vaccines,” said Dortmund immunologist Carsten Watzl of Augsburger Allgemeine .
Also interesting: is Novavax a dead vaccine? *
However, all previous data and findings mainly relate to the alpha variant, which has been almost completely replaced by Delta in Germany. According to experts, the new Omikron B1.1.529 * variant will soon have a strong influence on the infection process. “This vaccine will also have to be adapted to Omikron,” wrote Carsten Watzl, Secretary General of the German Society for Immunology, recently with a view to the Novavax agent on Twitter.
Novavax: Protein-based vaccine is said to be “better than vector vaccines”
The government has high hopes for Novavax’s corona vaccine. Because some have concerns about the vector and mRNA vaccines. Thuringia’s Prime Minister Bodo Ramelow (left) hopes that as soon as Novavax is also vaccinated in Germany, the reluctance to vaccinate – especially in the East – will decrease, as the German Press Agency (dpa) reports.
However, it will take a while before Novavax is also vaccinated in Germany *. Concrete delivery dates are not yet known, “the Federal Ministry of Health is interested in the fastest possible delivery,” it says on echo24.de request.
According to dpa , the EU Commission signed a contract for a total of up to 200 million cans in August. This includes an option for 100 million doses for the years 2022 and 2023. According to the Brussels authority, the first doses are expected to arrive in the Member States in the first few months of 2022. The EU countries have ordered around 27 million cans for the first three months. * echo24.de is an offer from IPPEN.MEDIA.
List of rubric lists: © Frank Hoermann / SVEN SIMON / dpa
